← Back to Home

FDA Lifts Clinical Hold on ARD-101; New Prader-Willi Syndrome Trial Still Awaiting Planning

Following additional cardiac safety studies, development of this oral drug candidate targeting hunger can move forward. But the original trials were terminated early, and the efficacy signals they yielded still need to be tested in a new Phase 3 study.

By SURL BioNews

For people with Prader-Willi syndrome (PWS) and their families, insatiable hunger often shapes daily care. ARD-101, an oral drug candidate being developed to address this symptom, now has another opportunity to advance: Aardvark Therapeutics announced on October 22 that the U.S. Food and Drug Administration (FDA) had lifted its clinical hold. Before patient trials can resume, however, further discussions with the regulator are still needed on the design of a new Phase 3 trial.

PWS is a rare genetic disorder characterized in part by intense, persistent hunger. ARD-101 is designed to activate bitter taste receptors in the gut, stimulating the release of gut peptide hormones involved in signaling hunger and satiety. This proposed mechanism remains under clinical investigation, and the drug has not received FDA approval.

The development interruption began in February this year. After routine safety monitoring in a separate study of healthy volunteers detected reversible electrocardiogram changes, the company voluntarily paused dosing in the Phase 3 HERO trial and its open-label extension trial on February 27. The FDA subsequently imposed a formal hold in May. Both patient trials were later terminated, so the lifting of the hold does not mean enrollment in the original trials will directly resume.

To address the safety concerns, Aardvark conducted an additional electrocardiogram study in healthy volunteers and an in vitro study of the cardiac sodium ion channel NaV1.5. According to the company’s announcement, no cardiac events were observed in the additional electrocardiogram study at the tested doses of 200 or 400 milligrams per dose, twice daily. Dow Jones Newswires also reported on these additional tests and the lifting of the hold. However, the absence of events under specific study conditions does not establish that the risks of long-term use have been fully ruled out.

Beyond safety, the efficacy evidence also leaves unanswered questions. In its summary of exploratory results released by the company on October 23, the Foundation for Prader-Willi Research (FPWR) noted that the HERO trial assessed symptoms using the caregiver-completed HQ-CT questionnaire on food-related behavior, with lower scores indicating improvement. Scores declined in both the treatment and placebo groups, with slightly greater improvement in the treatment group through Week 8. After dosing stopped, the treatment group returned to near baseline, while the placebo group retained more of its improvement.

These changes offer leads for further research but are insufficient to establish efficacy. The trial’s early termination and limited number of participants, particularly the smaller amount of data from later visits, constrain the interpretation of comparisons between groups and changes after dosing stopped. FPWR also emphasized this limitation and disclosed that it had invested in Aardvark in 2021 and 2024. Its summary of the results should be considered alongside this financial interest.

The next key step is to turn the development opportunity created by the lifting of the hold into a trial that can test these questions. As of FPWR’s October 23 update, enrollment dates, locations, age criteria, and whether participants from the previous trials could join the new Phase 3 study had not been announced. For families waiting for treatment options, the path to research has reopened, but whether ARD-101 can safely and consistently reduce excessive hunger remains a question for the new trial to answer.

References

  1. Aardvark Therapeutics via SEC
  2. Dow Jones Newswires via MarketScreener
  3. Foundation for Prader-Willi Research